4582.T
SymBio Pharmaceuticals Limited
グロース · 医薬品 · 医薬品 · JP
JPY 61.00
−1.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3B | 1.3B | 2.5B | 5.6B | 10.0B |
| Cost of Revenue | 60.6M | 360.3M | 579.7M | 1.2B | 2.4B |
| Gross Profit | 172.8M | 947.3M | 1.9B | 4.4B | 7.6B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 2.5B | 5.4B | 5.8B | 5.2B | 5.6B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.5B | 5.4B | 5.8B | 5.2B | 5.6B |
| Cost and Expenses | 6.9B | 5.7B | 6.3B | 6.4B | 8.0B |
| Operating Income (EBIT) | (5.6B) | (4.4B) | (3.9B) | (811.0M) | 2.0B |
| Non-Operating | |||||
| Interest Income | 2.2M | 4.2M | 32.1M | 12.0M | 98.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | (49.5M) | (207.2M) | 187.5M | 75.5M | 36.3M |
| Non-Operating Income (excl Interest) | — | 26.5M | 192.6M | 120.8M | 139.1M |
| EBT (Pre-Tax Income) | (2.4B) | (4.7B) | (3.8B) | (1.2B) | 2.1B |
| Income Tax Expense | 14.0M | 27.6M | 26.5M | 767.4M | 927.0M |
| Bottom Line | |||||
| Net Income | (5.9B) | (4.8B) | (3.8B) | (2.0B) | 1.2B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.9B) | (4.8B) | (3.8B) | (2.0B) | 1.2B |
| Per Share | |||||
| Basic EPS | (¥106) | (¥95) | (¥85) | (¥49) | ¥30 |
| Diluted EPS | (¥106) | — | — | — | ¥30 |
| Revenue Per Share | ¥19 | ¥26 | ¥54 | ¥140 | ¥256 |
| Shares | |||||
| Basic Shares Outstanding | 66.9M | 50.2M | 45.1M | 39.9M | 39.0M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | — | — | (715.0M) | 2.1B |
| D&A | — | — | — | 96.0M | 98.1M |
| EBIT | (5.6B) | (4.4B) | (3.9B) | (811.0M) | 2.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026